FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:PRKAB2-RFWD2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: PRKAB2-RFWD2
FusionPDB ID: 68615
FusionGDB2.0 ID: 68615
HgeneTgene
Gene symbol

PRKAB2

RFWD2

Gene ID

5565

64326

Gene nameprotein kinase AMP-activated non-catalytic subunit beta 2COP1 E3 ubiquitin ligase
Synonyms-CFAP78|FAP78|RFWD2|RNF200
Cytomap

1q21.1

1q25.1-q25.2

Type of geneprotein-codingprotein-coding
Description5'-AMP-activated protein kinase subunit beta-25'-AMP-activated protein kinase, beta-2 subunitAMP-activated protein kinase beta 2 non-catalytic subunitAMPK beta 2AMPK beta-2 chainAMPK subunit beta-2protein kinase, AMP-activated, beta 2 non-catalytic E3 ubiquitin-protein ligase COP1E3 ubiquitin-protein ligase RFWD2RING finger protein 200RING-type E3 ubiquitin transferase RFWD2constitutive photomorphogenesis protein 1 homologconstitutive photomorphogenic protein 1putative ubiquitin ligase COP1ri
Modification date2020032720200313
UniProtAcc..
Ensembl transtripts involved in fusion geneENST idsENST00000254101, ENST00000425272, 
ENST00000496858, 
ENST00000308769, 
ENST00000367669, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score3 X 3 X 2=1828 X 17 X 12=5712
# samples 327
** MAII scorelog2(3/18*10)=0.736965594166206
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
log2(27/5712*10)=-4.40296466697827
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: PRKAB2 [Title/Abstract] AND RFWD2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: PRKAB2 [Title/Abstract] AND RFWD2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)PRKAB2(146638424)-RFWD2(176118212), # samples:1
Anticipated loss of major functional domain due to fusion event.PRKAB2-RFWD2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PRKAB2-RFWD2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PRKAB2-RFWD2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PRKAB2-RFWD2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneRFWD2

GO:0010212

response to ionizing radiation

19805145



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:146638424/chr1:176118212)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across PRKAB2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across RFWD2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000254101PRKAB2chr1146638424-ENST00000367669RFWD2chr1176118212-2312556611989642
ENST00000254101PRKAB2chr1146638424-ENST00000308769RFWD2chr1176118212-1930556611929623
ENST00000425272PRKAB2chr1146638424-ENST00000367669RFWD2chr1176118212-2068312541745563
ENST00000425272PRKAB2chr1146638424-ENST00000308769RFWD2chr1176118212-1686312541685543

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000254101ENST00000367669PRKAB2chr1146638424-RFWD2chr1176118212-0.0010601380.9989398
ENST00000254101ENST00000308769PRKAB2chr1146638424-RFWD2chr1176118212-0.0019288710.99807113
ENST00000425272ENST00000367669PRKAB2chr1146638424-RFWD2chr1176118212-0.0002808970.9997191
ENST00000425272ENST00000308769PRKAB2chr1146638424-RFWD2chr1176118212-0.0009073790.9990926

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PRKAB2-RFWD2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
PRKAB2chr1146638424RFWD2chr117611821231286FFVDGQWVHDPSEESHAAQLQILMEF
PRKAB2chr1146638424RFWD2chr1176118212556165FFVDGQWVHDPSEESHAAQLQILMEF

Top

Potential FusionNeoAntigen Information of PRKAB2-RFWD2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PRKAB2-RFWD2_146638424_176118212.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B18:01EESHAAQL0.99030.67381220
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B50:02SEESHAAQL0.99290.63881120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B44:03SEESHAAQL0.97570.85051120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B45:01SEESHAAQL0.96590.86821120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B39:13SEESHAAQL0.67980.90211120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B50:01SEESHAAQL0.47120.79551120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B35:04DPSEESHAA0.46990.9467918
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B35:02DPSEESHAA0.46990.9467918
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B41:01SEESHAAQL0.41790.7781120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B15:18VHDPSEESH0.39240.6945716
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B44:05EESHAAQLQI0.97140.62861222
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B39:06VHDPSEESHAA0.99950.8257718
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B35:03DPSEESHAAQL0.98430.5934920
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B35:02DPSEESHAAQL0.97460.8187920
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B35:04DPSEESHAAQL0.97460.8187920
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B38:02EESHAAQLQIL0.96010.93111223
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B38:01EESHAAQLQIL0.95670.93771223
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B40:06SEESHAAQL0.99960.61681120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B39:08SEESHAAQL0.73440.73331120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B39:09SEESHAAQL0.66820.53971120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B39:05SEESHAAQL0.60850.80311120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B39:05VHDPSEESH0.54230.7925716
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B35:12DPSEESHAA0.46990.9467918
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B78:01DPSEESHAA0.46650.6379918
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B39:10DPSEESHAA0.09740.8536918
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B44:10EESHAAQLQI0.95990.65081222
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B54:01HDPSEESHAA0.88750.528818
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B39:05VHDPSEESHAA0.99860.7953718
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B35:12DPSEESHAAQL0.97460.8187920
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B39:10DPSEESHAAQL0.90150.8291920
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B18:05EESHAAQL0.99030.67381220
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B18:03EESHAAQL0.98650.65861220
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B18:06EESHAAQL0.98580.70311220
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B18:11EESHAAQL0.97530.57711220
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B40:04SEESHAAQL0.99940.72281120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B44:26SEESHAAQL0.97570.85051120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B44:13SEESHAAQL0.97570.85051120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B44:07SEESHAAQL0.97570.85051120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B18:11SEESHAAQL0.7460.75821120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B18:08SEESHAAQL0.74130.89641120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B39:11SEESHAAQL0.740.64371120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B18:06SEESHAAQL0.69380.89591120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B39:31SEESHAAQL0.68170.81851120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B39:02SEESHAAQL0.6490.90021120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B18:03SEESHAAQL0.63810.86831120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B50:04SEESHAAQL0.47120.79551120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B50:05SEESHAAQL0.47120.79551120
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B35:09DPSEESHAA0.46990.9467918
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B39:11VHDPSEESH0.39480.6903716
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B78:02DPSEESHAA0.33260.6686918
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B39:11VHDPSEESHA0.95940.7488717
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B39:11VHDPSEESHAA0.99720.7111718
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B35:09DPSEESHAAQL0.97460.8187920
PRKAB2-RFWD2chr1146638424chr1176118212556HLA-B38:05EESHAAQLQIL0.95670.93771223

Top

Potential FusionNeoAntigen Information of PRKAB2-RFWD2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PRKAB2-RFWD2_146638424_176118212.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0305DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0401DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0401VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0401GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0401FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0409DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0409VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0422DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0433DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0433VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0433GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0433FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0434DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0434VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0434GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0434FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0435DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0435VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0438DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0438VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0438GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0462DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0462VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0462FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0463DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0463VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0463GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0463FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0464DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0464VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0464GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0464FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0466DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0466VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0466GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0472DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0472VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0472GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0472FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0474DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0474VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0475DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0476DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0476VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0476GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB1-0476FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0101DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0101VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0101FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0101GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0104DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0104VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0104FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0104GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0105DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0105VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0105FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0105GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0108DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0108VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0108FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0108GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0109DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0109VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0109FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0111DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0111VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0111FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0111GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0112DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0112VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0112FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0112GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0113DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0113VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0113FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0113GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0114DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0114VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0114FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0202DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0202VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0205DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0209DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0209VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0210DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0210VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0211DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0212DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0212VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0213DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0213VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0213GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0213FVDGQWVHDPSEESH116
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0215DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0215VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0216DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0216VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0217DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0217VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0218DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0218VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0219DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0219VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0219GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0220DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0220VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0221DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0221VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0222DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0222VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0222GQWVHDPSEESHAAQ419
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0223DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0223VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0225DGQWVHDPSEESHAA318
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0225VDGQWVHDPSEESHA217
PRKAB2-RFWD2chr1146638424chr1176118212556DRB3-0303DGQWVHDPSEESHAA318

Top

Fusion breakpoint peptide structures of PRKAB2-RFWD2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
10558WVHDPSEESHAAQLPRKAB2RFWD2chr1146638424chr1176118212556

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PRKAB2-RFWD2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN10558WVHDPSEESHAAQL-7.62292-7.81302
HLA-B14:023BVN10558WVHDPSEESHAAQL-5.76779-6.53379
HLA-B52:013W3910558WVHDPSEESHAAQL-5.88073-6.64673
HLA-B52:013W3910558WVHDPSEESHAAQL-4.87415-5.06425
HLA-A11:014UQ210558WVHDPSEESHAAQL-11.6143-11.8044
HLA-A11:014UQ210558WVHDPSEESHAAQL-8.0735-8.8395
HLA-A24:025HGA10558WVHDPSEESHAAQL-8.18765-8.37775
HLA-A24:025HGA10558WVHDPSEESHAAQL-6.96792-7.73392
HLA-B27:056PYJ10558WVHDPSEESHAAQL-4.95652-5.72252
HLA-B44:053DX810558WVHDPSEESHAAQL-8.31628-9.08228
HLA-B44:053DX810558WVHDPSEESHAAQL-3.65224-3.84234

Top

Vaccine Design for the FusionNeoAntigens of PRKAB2-RFWD2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
PRKAB2-RFWD2chr1146638424chr11761182121120SEESHAAQLTCAGAGGAATCACATGCAGCCCAACTA
PRKAB2-RFWD2chr1146638424chr11761182121220EESHAAQLGAGGAATCACATGCAGCCCAACTA
PRKAB2-RFWD2chr1146638424chr11761182121222EESHAAQLQIGAGGAATCACATGCAGCCCAACTACAGATT
PRKAB2-RFWD2chr1146638424chr11761182121223EESHAAQLQILGAGGAATCACATGCAGCCCAACTACAGATTCTT
PRKAB2-RFWD2chr1146638424chr1176118212716VHDPSEESHGTTCATGATCCATCAGAGGAATCACAT
PRKAB2-RFWD2chr1146638424chr1176118212717VHDPSEESHAGTTCATGATCCATCAGAGGAATCACATGCA
PRKAB2-RFWD2chr1146638424chr1176118212718VHDPSEESHAAGTTCATGATCCATCAGAGGAATCACATGCAGCC
PRKAB2-RFWD2chr1146638424chr1176118212818HDPSEESHAACATGATCCATCAGAGGAATCACATGCAGCC
PRKAB2-RFWD2chr1146638424chr1176118212918DPSEESHAAGATCCATCAGAGGAATCACATGCAGCC
PRKAB2-RFWD2chr1146638424chr1176118212920DPSEESHAAQLGATCCATCAGAGGAATCACATGCAGCCCAACTA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
PRKAB2-RFWD2chr1146638424chr1176118212116FVDGQWVHDPSEESHTTTGTGGATGGACAGTGGGTTCATGATCCATCAGAGGAATCACAT
PRKAB2-RFWD2chr1146638424chr1176118212217VDGQWVHDPSEESHAGTGGATGGACAGTGGGTTCATGATCCATCAGAGGAATCACATGCA
PRKAB2-RFWD2chr1146638424chr1176118212318DGQWVHDPSEESHAAGATGGACAGTGGGTTCATGATCCATCAGAGGAATCACATGCAGCC
PRKAB2-RFWD2chr1146638424chr1176118212419GQWVHDPSEESHAAQGGACAGTGGGTTCATGATCCATCAGAGGAATCACATGCAGCCCAA

Top

Information of the samples that have these potential fusion neoantigens of PRKAB2-RFWD2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
N/APRKAB2-RFWD2chr1146638424ENST00000254101chr1176118212ENST00000308769DA824273

Top

Potential target of CAR-T therapy development for PRKAB2-RFWD2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to PRKAB2-RFWD2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to PRKAB2-RFWD2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource